Insider Purchase: Kura Oncology CEO Acquires 50,000 Shares at $8.20

Rhea-AI Filing Summary

Reporting person: Troy Edward Wilson, President & CEO and a director of Kura Oncology, Inc. (KURA). On 09/08/2025 he acquired 50,000 shares of the issuer's common stock in multiple trades at a weighted average purchase price of $8.2029 per share. After the purchase, Mr. Wilson beneficially owns 100,968 shares directly and holds additional indirect interests of 279,194 shares through the One Fish Two Fish Revocable Trust and 300,000 shares through the Lorax Charitable Remainder Unitrust. The Form 4 was signed by an attorney-in-fact on behalf of Mr. Wilson on 09/09/2025. The filing discloses that trade prices ranged from $8.135 to $8.24 and that the reported price is a weighted average.

Positive

• Insider purchase disclosed: The CEO and director acquired 50,000 shares, increasing his direct stake.
• Transparency on holdings: Filing details direct ownership (100,968 shares) and significant indirect holdings (279,194 and 300,000 shares).
• Price detail provided: Trade price range ($8.135 to $8.24) and weighted average ($8.2029) are disclosed.

Negative

• None.

Insights

Securities Analyst

TL;DR: Insider purchased 50,000 shares at a weighted average of $8.2029; filing documents direct and indirect holdings.

This Form 4 reports a standard open-market acquisition by Troy E. Wilson, the companys President & CEO and a director. The transaction occurred in multiple trades on 09/08/2025 with execution prices between $8.135 and $8.24, reported as a weighted average of $8.2029. Post-transaction direct beneficial ownership is documented at 100,968 shares, with materially larger indirect holdings via a revocable trust (279,194 shares) and a charitable unitrust (300,000 shares). The filing is routine and provides necessary transparency on insider holdings and purchases.

Corporate Governance Expert

TL;DR: Form 4 is a standard disclosure of an insider purchase and existing indirect ownership structures.

The submission complies with Section 16 reporting obligations by disclosing a purchase and detailing both direct and indirect ownership vehicles. It specifies the role of the reporting person as President & CEO and director, and includes an explanatory note on trade price range and weighted average. The filing is procedural and supplies investors with clarity on the executives aggregate equity exposure across personal and trust accounts.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

WILSON TROY EDWARD

(Last) (First) (Middle)

C/O KURA ONCOLOGY, INC.

12730 HIGH BLUFF DRIVE, SUITE 400

(Street)

SAN DIEGO CA 92130

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Kura Oncology, Inc. [ KURA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President & CEO

3. Date of Earliest Transaction (Month/Day/Year)
09/08/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/08/2025		P		50,000	A	$8.2029(1)	100,968	D
Common Stock								279,194	I	by One Fish Two Fish Revocable Trust
Common Stock								300,000	I	by Lorax Charitable Remainder Unitrust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was executed in multiple trades at prices ranging from $8.135 to $8.24. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakesto provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

	/s/ Teresa Bair, Attorney-in-fact for Troy E. Wilson	09/09/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Who filed the Form 4 for KURA and what is their role?

The Form 4 was filed for Troy Edward Wilson, who is the President & CEO and a director of Kura Oncology, Inc.

What transaction is reported on the KURA Form 4 dated 09/08/2025?

The filing reports the acquisition of 50,000 shares of common stock on 09/08/2025 in multiple trades at a weighted average price of $8.2029 per share.

How many shares does Troy E. Wilson beneficially own after the reported transaction?

After the transaction Mr. Wilson beneficially owns 100,968 shares directly, plus 279,194 shares indirectly via a revocable trust and 300,000 shares indirectly via a charitable unitrust.

What price range were the trades executed at?

The trades were executed at prices ranging from $8.135 to $8.24; the reported price is the weighted average of $8.2029.

When was the Form 4 signed and by whom?

The Form 4 was signed on behalf of Troy E. Wilson by Teresa Bair, Attorney-in-fact on 09/09/2025.